Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

But turning this crisis into an opportunity is possible. To mitigate the effects of the funding freeze, Bekker said swift ...

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

Without public health surveillance, officials trying to tackle outbreaks, identify threats and evaluate treatments are working ‘in the darkness of ignorance.’ ...

A Lancet study shows promising results for an annual HIV prevention injection, lenacapavir. In Stage 1 trials, 40 HIV-negative participants had no significant side effects ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Nov. 25, 2024 — A new study reveals significant progress in the global fight against HIV/AIDS, alongside a stark ... typically cause liver infections. They can, however, also infect other ...